Literature DB >> 28411681

Breast PET/MR Imaging.

Amy Melsaether1, Linda Moy2.   

Abstract

Breast and whole-body PET/MR imaging is being used to detect local and metastatic disease and is being investigated for potential imaging biomarkers, which may eventually help personalize treatments and prognoses. This article provides an overview of breast and whole-body PET/MR exam techniques, summarizes PET and MR breast imaging for lesion detection, outlines investigations into multi-parametric breast PET/MR, looks at breast PET/MR in the setting of neo-adjuvant chemotherapy, and reviews the pros and cons of whole-body PET/MR in the setting of metastatic or suspected metastatic breast cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast MR imaging; Breast PET; Breast PET/MR imaging; Breast cancer; Multiparametric; PET/MR imaging; Whole-body PET/MR imaging

Mesh：

Year:  2017        PMID： 28411681      PMCID： PMC6080619          DOI： 10.1016/j.rcl.2016.12.011

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN： 0033-8389            Impact factor:   2.303


  64 in total

1.  Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography.

Authors:  Habib Zaidi; Marie-Louise Montandon; Daniel O Slosman
Journal:  Med Phys       Date:  2003-05       Impact factor: 4.071

2.  Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.

Authors:  Lino M Sawicki; Johannes Grueneisen; Benedikt M Schaarschmidt; Christian Buchbender; James Nagarajah; Lale Umutlu; Gerald Antoch; Sonja Kinner
Journal:  Eur J Radiol       Date:  2015-12-19       Impact factor: 3.528

3.  Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

Authors:  Ivan Jambor; Anna Kuisma; Susan Ramadan; Riikka Huovinen; Minna Sandell; Sami Kajander; Jukka Kemppainen; Esa Kauppila; Joakim Auren; Harri Merisaari; Jani Saunavaara; Tommi Noponen; Heikki Minn; Hannu J Aronen; Marko Seppänen
Journal:  Acta Oncol       Date:  2015-04-02       Impact factor: 4.089

4.  Longitudinal, intermodality registration of quantitative breast PET and MRI data acquired before and during neoadjuvant chemotherapy: preliminary results.

Authors:  Nkiruka C Atuegwu; Xia Li; Lori R Arlinghaus; Richard G Abramson; Jason M Williams; A Bapsi Chakravarthy; Vandana G Abramson; Thomas E Yankeelov
Journal:  Med Phys       Date:  2014-05       Impact factor: 4.071

5.  Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.

Authors:  Nariya Cho; Seock-Ah Im; Keon Wook Kang; In-Ae Park; In Chan Song; Kyung-Hun Lee; Tae-Yong Kim; Hyunjong Lee; In Kook Chun; Hai-Jeon Yoon; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2015-09-17       Impact factor: 5.315

6.  Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Antonio C Wolff; Edward Gabrielson; Hind Warzecha; Stacie Jeter; David A Bluemke; Richard Wahl; Vered Stearns
Journal:  Breast Cancer Res Treat       Date:  2011-04-01       Impact factor: 4.872

7.  Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy.

Authors:  Roy A Raad; Kent P Friedman; Laura Heacock; Fabio Ponzo; Amy Melsaether; Hersh Chandarana
Journal:  J Magn Reson Imaging       Date:  2015-07-20       Impact factor: 4.813

8.  Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.

Authors:  Akshat C Pujara; Roy A Raad; Fabio Ponzo; Carolyn Wassong; James S Babb; Linda Moy; Amy N Melsaether
Journal:  Breast J       Date:  2016-02-04       Impact factor: 2.431

9.  Effectiveness of Breast MRI and (18)F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal Carcinoma.

Authors:  Na Young Jung; Sung Hoon Kim; Sung Hun Kim; Ye Young Seo; Jin Kyoung Oh; Hyun Su Choi; Won Jong You
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

Review 10.  The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Qiufang Liu; Chen Wang; Panli Li; Jianjun Liu; Gang Huang; Shaoli Song
Journal:  Biomed Res Int       Date:  2016-02-15       Impact factor: 3.411
View more
  3 in total

1.  A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis.

Authors:  Doris Leithner; Joao V Horvat; Blanca Bernard-Davila; Thomas H Helbich; R Elena Ochoa-Albiztegui; Danny F Martinez; Michelle Zhang; Sunitha B Thakur; Georg J Wengert; Anton Staudenherz; Maxine S Jochelson; Elizabeth A Morris; Pascal A T Baltzer; Paola Clauser; Panagiotis Kapetas; Katja Pinker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-13       Impact factor: 9.236

2.  Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy.

Authors:  Chikako Sekine; Nachiko Uchiyama; Chikashi Watase; Takeshi Murata; Sho Shiino; Kenjiro Jimbo; Eriko Iwamoto; Shin Takayama; Hiroaki Kurihara; Kaishi Satomi; Masayuki Yoshida; Takayuki Kinoshita; Akihiko Suto
Journal:  Mol Clin Oncol       Date:  2021-12-24

Review 3.  Multimodality reporter gene imaging: Construction strategies and application.

Authors:  Mengting Li; Yichun Wang; Mei Liu; Xiaoli Lan
Journal:  Theranostics       Date:  2018-04-18       Impact factor: 11.556
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.